The new facility would also have access to the company's mRNA development engine, according to Moderna. The goal of the collaboration is to support Canada with direct access to rapid pandemic response capabilities that could be activated on an urgent basis, as well as provide access to Moderna's vaccines in development for respiratory viruses such as COVID-19, seasonal influenza, respiratory syncytial virus (RSV), and potential other vaccines, pending licensure, the company said.

Moderna said it's also in discussions with other countries about similar collaborations.

Autolus, Moderna ink license agreement
Biopharmaceutical company Autolus Therapeutics has granted Moderna exclusive license to develop and market mRNA therapeutics that include Autolus' binding...

EMA takes positive stance on Moderna COVID-19 vaccine for adolescents
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use has taken a positive position on marketing authorization for Moderna's...

Moderna files U.S. EUA for COVID-19 vaccine in adolescents
Moderna announced it has requested an emergency use authorization (EUA) from the U.S. Food and Drug Administration for its COVID-19 vaccine in adolescents.

Moderna, Medison partner on Moderna's COVID-19 vaccine
Moderna and Medison Pharma announced that they are entering into a marketing agreement for Moderna's COVID-19 vaccine across central Europe and Israel.

Moderna initiates rolling BLA for COVID-19 vaccine
Moderna has started the rolling submission process with the U.S. Food and Drug Administration for a biologics license application (BLA) for the use of...